康缘药业(600557) - 2015 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders was CNY 81,617,680.53, representing a year-on-year increase of 12.97%[9] - Operating income for the period reached CNY 658,029,406.40, reflecting an increase of 11.45% compared to the same period last year[9] - Basic earnings per share increased by 14.29% to CNY 0.16 per share[9] - Net profit for Q1 2015 reached CNY 81,898,748.57, representing a growth of 12.66% from CNY 72,618,713.71 in Q1 2014[39] - Total operating revenue for Q1 2015 was CNY 658,029,406.40, an increase of 11.47% compared to CNY 590,422,544.24 in the same period last year[39] - The company reported a gross profit margin of approximately 14.5% for Q1 2015, compared to 12.5% in Q1 2014[39] Cash Flow - The net cash flow from operating activities was CNY 137,637,241.14, up 74.80% year-on-year[9] - The total cash inflow from operating activities for Q1 2015 was CNY 704,374,232.51, an increase of 18.4% compared to CNY 595,199,228.96 in the same period last year[45] - The net cash flow from operating activities was CNY 137,637,241.14, up 74.7% from CNY 78,737,914.76 in Q1 2014[45] - Cash inflow from financing activities was CNY 102,474,286.67, significantly higher than CNY 40,000,000.00 in the same quarter last year[46] - The net cash flow from investing activities was -CNY 147,629,474.07, worsening from -CNY 106,180,107.14 in Q1 2014[46] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,137,737,481.21, a decrease of 0.41% compared to the end of the previous year[9] - The company's current assets decreased to CNY 2,119,278,835.19 from CNY 2,254,976,629.96, reflecting a decline of approximately 6%[30] - The total liabilities decreased to CNY 1,499,584,509.45 from CNY 1,598,724,939.34, a reduction of about 6%[31] - Total liabilities as of the end of Q1 2015 amounted to CNY 1,008,265,367.71, a decrease from CNY 1,073,818,699.99 at the end of the previous year[36] - The company's equity increased to CNY 2,638,152,971.76 from CNY 2,556,246,782.21, marking an increase of approximately 3.2%[31] Shareholder Information - The total number of shareholders at the end of the reporting period was 29,955[14] - Jiangsu Kangyuan Group Co., Ltd. held 27.34% of the shares, making it the largest shareholder[14] Changes in Assets - Cash and cash equivalents decreased by 38.27% to ¥341,697,499.01 due to loan repayments during the reporting period[18] - Other receivables decreased by 68.96% to ¥25,962,262.66 primarily from the collection of various personnel loans and sales staff's advances[18] - Deferred tax assets decreased by 37.07% to ¥4,735,900.71 due to a reduction in deductible deferred tax assets[18] - Other non-current assets increased by 56.37% to ¥160,038,252.19 mainly due to an increase in prepaid engineering costs[18] - Accounts payable increased by 48.10% to ¥303,733,681.85 due to an increase in payables for purchases[18] - Inventory levels rose to CNY 161,288,950.63 from CNY 144,615,901.04, indicating an increase of about 11.4%[30] Borrowings and Financing - Short-term borrowings due within one year decreased by 55.36% to ¥25,000,000.00 due to a reduction in long-term borrowings maturing within the year[19] - The company maintained long-term borrowings of CNY 125,000,000.00, unchanged from the previous year[36] - The company raised a total of ¥360,000,200.92 from a non-public offering of 14,931,572 shares at ¥24.11 per share, with a net amount of ¥350,400,200.92 after deducting issuance costs[23] Other Financial Metrics - The weighted average return on equity decreased to 3.21%, down 0.56 percentage points from the previous year[9] - Sales expenses for Q1 2015 were CNY 269,474,230.27, an increase of 12.09% from CNY 240,407,528.60 in Q1 2014[39] - Other payables increased to CNY 209,457,316.18 in Q1 2015, compared to CNY 182,991,384.19 in Q1 2014[36]